<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361348</url>
  </required_header>
  <id_info>
    <org_study_id>20050137</org_study_id>
    <nct_id>NCT00361348</nct_id>
    <nct_alias>NCT00964509</nct_alias>
  </id_info>
  <brief_title>Palifermin DDI (Drug Drug Interaction)</brief_title>
  <official_title>An Open-label, Randomized, 2-part, Parallel Design Study to Characterize the Effect of Heparin on Palifermin Pharmacokinetics and the Effect of Palifermin on Heparin Pharmacodynamics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Paliferim interacts with Heparin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heparin has been shown to modulate binding of palifermin to the KGF receptor. Therefore, as&#xD;
      part of a post-marketing regulatory commitment with the Food and Drug Administration (FDA),&#xD;
      the purpose of this study is to characterize the potential pharmacokinetic and&#xD;
      pharmacodynamic drug-drug interaction between a continuous IV infusion of heparin and an IV&#xD;
      bolus injection of palifermin. If an interaction is observed during co-administration, it is&#xD;
      expected that the outcome would be modulation of clearance of palifermin or a change in&#xD;
      heparin activity. Although not commonly conducted, the literature describes heparin drug-drug&#xD;
      interaction studies conducted in healthy subjects using both subcutaneous (Grimaudo et&#xD;
      al,1988; Kroon et al, 1992) and intravenous (Caplain at al, 1999; Noveck &amp; Hubbard, 2004;&#xD;
      Spowart et al, 1988) formulations. Based on these experiences, it is appropriate to&#xD;
      investigate heparin drug-drug interactions in healthy subjects.&#xD;
&#xD;
      In this study, subjects will receive a single 60 mcg/kg dose of palifermin either as&#xD;
      monotherapy or in conjunction with a continuous heparin infusion. The 60 mcg/kg dose of&#xD;
      palifermin explored in this study is identical to the current recommended daily dosage for&#xD;
      patients with hematologic malignancies who were undergoing autologous PBPC transplantation&#xD;
      after receiving total body irradiation and high-dose chemotherapy: 3 consecutive days&#xD;
      administered in two cycles with a 5-day non-dosing interval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of a continuous intravenous (IV) infusion of unfractionated heparin on the single-dose pharmacokinetics (PK) of palifermin in healthy subjects.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect (activated partial thromboplastin time, aPTT) of a single dose of palifermin on unfractionated heparin pharmacodynamics [(PD), AUCaPTT, 0-6, AUCaPTT, 0-24].</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of a single 60 µg/kg intravenous dose of palifermin with or without a continuous IV infusion of heparin.</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>45</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palifermin + Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_label>Palifermin + Heparin</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_label>Palifermin + Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Inclusion: Baseline aPTT values for all subjects must be within&#xD;
        normal range. In addition, all subjects must also test negative for occult blood in the&#xD;
        stool, have no history of bleeding disorders or no use of aspirin or NSAIDs within 14 days&#xD;
        of study Day 1. Exclusion Criteria: - Exclusion: The study will also exclude subjects who&#xD;
        have any evidence or history of thrombocytopenia, heparin-induced thrombocytopenia or other&#xD;
        contraindications to heparin (e.g., recent surgeries).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Biovitrum AB (publ)</affiliation>
  </overall_official>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>August 4, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2006</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palifermin</keyword>
  <keyword>drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

